Division of Hematology, Mayo Clinic , Rochester , MN , USA.
Division of Hematopathology, Mayo Clinic , Rochester , MN , USA.
Leuk Lymphoma. 2019 Oct;60(10):2483-2487. doi: 10.1080/10428194.2019.1581930. Epub 2019 Mar 7.
Myelodysplastic syndrome unclassifiable (MDS-U) is a small subtype of myelodysplastic syndromes (MDS). However, rare literature exists in terms of natural progression and clinical outcome of patients with MDS-U. In the present study, we investigated the characteristics and the clinical outcomes of patients categorized as MDS-U based on 2008 World Health Organization criteria (WHO) in a single center comparing to other MDS groups. Out of eight hundred and two patients who met WHO criteria for MDS at our institution, ninety patients (11%) were initially classified as MDS-U. Upon pathological review, only half of the cases were confirmed to be MDS-U. With follow up, half of the MDS-U cases were reclassified to another subtype. We found neither significant difference in median overall survival nor in risk of transformation to acute myeloid leukemia when comparing MDS-U to other MDS groups. Additional larger studies are needed to confirm our results.
骨髓增生异常综合征不能分类(MDS-U)是骨髓增生异常综合征(MDS)的一个小亚型。然而,关于 MDS-U 患者的自然病程和临床结局的罕见文献报道。在本研究中,我们通过与其他 MDS 组进行比较,基于 2008 年世界卫生组织(WHO)标准,对我院符合 MDS 诊断标准的 802 例患者中被归类为 MDS-U 的患者的特征和临床结局进行了研究。在我院符合 MDS 诊断标准的 802 例患者中,有 90 例(11%)患者最初被归类为 MDS-U。经病理复查,仅有一半的病例被确认为 MDS-U。随访后,MDS-U 患者中有一半被重新分类为另一种亚型。我们发现 MDS-U 与其他 MDS 组相比,中位总生存期或转化为急性髓系白血病的风险均无显著差异。需要进一步开展更大规模的研究来证实我们的结果。